Publications by authors named "Frederic Maury"
Article Synopsis
- The study evaluated the retention rates, safety, and predictive factors for the use of subcutaneous TNF inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) based on real-life data from 552 patients.
- Results indicated that golimumab (GOL) had a significantly higher retention rate compared to adalimumab (ADA), etanercept (ETN), and certolizumab pegol (CZP), especially when prescribed as the first treatment option.
- Predictive factors for treatment cessation included female sex, peripheral disease, and the line of treatment, with primary inefficiency being the most common reason for stopping treatment.
Front Med (Lausanne)
October 2022
Article Synopsis
- Previous studies showed that biosimilars (bsDMARDs) and original treatments (boDMARDs) are similarly effective and safe, but less is known about their performance in naïve patients starting treatment for the first time.
- This study aimed to compare the treatment retention rates of bsDMARDs and boDMARDs across different diseases (like RA, SpA, and PsA) and specific molecules (etanercept and adalimumab), while also identifying predictive factors influencing treatment retention.
- Results indicated that bsDMARDs had a longer retention rate than boDMARDs (39 months vs. 23 months), particularly for etanercept in rheumatoid arthritis patients, and treatments containing citrate showed even better retention.*
